Anti‐CD20 mAb maintenance therapy vs observation
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher grade 3/4 adverse events compared with observation (low certainty).
1 finding from 1 review
- Rate ratio 1.34 [1.06, 1.71]5 studies · 1284 participantsLow